Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation

Tegg, Elizabeth; Griffiths, A. E.; Lowenthal, RM; Tuck, DM; Harrup, Rosemary; Marsden, Kate; Jupe, D. M. L.; Ragg, SJ; Matthews, Jane P.

doi:10.1038/sj.bmt.1703272

Cited by 15 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HCT studies have focused on inflammatory biomarkers post-conditioning and/or serially evaluated to predict outcome 34,35. Higher levels post-HCT have been associated with increased transplantation related complications in some studies 34,36,37 and with worse survival in others 24,38. Schots and colleagues analyzed IL-6, interleukin-8 and tumor necrosis factor-alpha levels serially in 84 patients after HCT.…”

Section: Discussionmentioning

confidence: 99%

Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Artz

Wickrema

Dinner

et al. 2008

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

We tested the independent prognostic impact of two commonly used biomarkers, C-reactive protein (CRP) and interleukin-6 (IL-6), on allogeneic hematopoietic cell transplantation (HCT) outcomes. Consecutive patients who underwent a uniform reduced intensity regimen of fludarabine, melphalan and alemtuzumab were evaluated. Cryopreserved sera drawn before conditioning was available to measure CRP and IL-6 levels from 81 and 79 patients, respectively. Patients having CRP values above the median of 18.5 mg/L had significantly more grade 3 to 4 hepatic toxicity (P = 0.08), longer HCT hospital stay (P = 0.005), more aGVHD (P = 0.003), greater non-relapse mortality (NRM) (P =0.01) and inferior overall survival (P =0.02). Higher baseline CRP also correlated with more grade 3 to 4 infectious toxicity (P = 0.09). In contrast, pre-HCT IL-6 levels above the median of 78.3 pg/mL, did not confer a statistically significant increased risk of toxicities or mortality. Elevated hematopoietic cell transplantation-comorbidity index (HCT-CI) did not predict for any measure of HCT morbidity. After adjustment for disease status, comorbidity, performance status and age, elevated CRP concentration remained predictive of NRM. CRP holds promise as a readily available serum biomarker that can be measured prior to HCT conditioning to enhance estimates of transplantation tolerance.

show abstract

Section: Discussionmentioning

confidence: 99%

Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Artz

Wickrema

Dinner

et al. 2008

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…28 This possible rescue of chemotherapy-treated tumour cells by IL-6 may explain why serum IL-6 levels postautologous transplantation were shown to be predictors of poor response after high-dose chemotherapy and autologous transplantation in various cancers. 46 We also have to emphasize that the anti-IL-6 mAb might have potentiated the apoptotic effect of DEX given just before HDM since numerous studies have shown that IL-6 can block the DEX-induced apoptosis of myeloma cells in vitro. This was the reason why we decided to inject DEX just before HDM treatment.…”

Section: Discussionmentioning

confidence: 99%

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

Rossi

Fégueux

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. In all, 24 consecutive patients with MM in first-line therapy received DEX for 4 days, followed by melphalan (HDM: 140 mg/m 2 ) and autologous stem cell transplantation (ASCT). The anti-IL-6 monoclonal antibody (mAb) (B-E8) was given till haematological recovery, starting 1 day before DEX. Results were historically compared to MM patients treated with HDM 140 and 200 mg/m 2 . Our results show (1) that B-E8 was able to fully neutralize IL-6 activity in vivo before and after HDM as shown by inhibition of C reactive protein (CRP) production; (2) no haematological toxicity; (3) a significant reduction of mucositis and fever; (4) a median event-free survival of 35 months and an overall survival of 68.2% at 5 years with a median follow-up of 72 months; and (5) the overall daily IL-6 production progressively increased on and after 7 days post-HDM, with the increased serum CRP levels. In the 5/24 patients with uncontrolled CRP production, a large IL-6 production was detected (320 lg/day) that could not possibly be neutralized by B-E8. These data show the feasibility to neutralize IL-6 in vivo with anti-IL-6 mAb in the context of HDM. Bone Marrow Transplantation (2005) 36, 771-779.

show abstract

“…Among non-orthopedic surgery studies, IL-6 on the day of haemopoietic stem cell transplantation predicted hospital length of stay (Tegg et al, 2001). Peri-operative lidocaine has been found to affect hospital length of stay for some abdominal surgeries.…”

Section: Early Post Surgical Status and Hospital Length Of Staymentioning

confidence: 99%

Biochemical Measurement of Injury and Inflammation in Musculoskeletal Surgeries

Kumbhare¹,

Parkinson²,

Dunlop³

et al. 2012

Orthopedic Surgery

View full text Add to dashboard Cite

Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation

Cited by 15 publications

References 27 publications

Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

Biochemical Measurement of Injury and Inflammation in Musculoskeletal Surgeries

Contact Info

Product

Resources

About